Inventor · disambiguated record
Ian Kirby
Also filed as: KIRBY IAN · KIRBY IAN G
28 granted patents·27 pending applications·393 citations·filing 1984–2025
97Inventor score
Top patents by PatentIndex Score
55 records- 0198US9234043B1Anti-human OX40L antibodiesKYMAB LTD·Filed 2015·Granted Jan 12, 2016·21 cites·20 claims
- 0298US9139653B1Anti-human OX40L antibodies and methods of treatmentKYMAB LTD·Filed 2015·Granted Sep 22, 2015·38 cites·27 claims
- 0397US9617338B1Antibodies and immunocytokinesKYMAB LTD·Filed 2016·Granted Apr 11, 2017·78 cites·20 claims
- 0497US9567399B1Antibodies and immunocytokinesKYMAB LTD·Filed 2016·Granted Feb 14, 2017·96 cites·21 claims
- 0597US9512229B2Synergistic combinations of OX40L antibodies for the treatment of GVHDKYMAB LTD·Filed 2016·Granted Dec 6, 2016·12 cites·30 claims
- 0696US10604576B2Antibodies and immunocytokinesKYMAB LTD·Filed 2017·Granted Mar 31, 2020·25 cites·14 claims
- 0796US9957323B2Anti-ICOS antibodiesKYMAB LTD·Filed 2017·Granted May 1, 2018·27 cites·26 claims
- 0896US9868790B2Synergistic combinations of OX40L antibodies for the treatment of GvHDKYMAB LTD·Filed 2017·Granted Jan 16, 2018·11 cites·29 claims
- 0996US9868789B2Synergistic combinations of OX40L antibodies for the treatment of GvHDKYMAB LTD·Filed 2017·Granted Jan 16, 2018·11 cites·19 claims
- 1094US11396550B2Methods of treating comprising administering anti-OX40L antibodiesKYMAB LTD·Filed 2017·Granted Jul 26, 2022·4 cites·54 claims
- 1194US10654935B2Methods of treating SLE with anti-OX40L antibodiesKYMAB LTD·Filed 2016·Granted May 19, 2020·7 cites·13 claims
- 1294US9587030B2Anti-hOX40L antibodies, uses, and methodsKYMAB LTD·Filed 2016·Granted Mar 7, 2017·14 cites·21 claims
- 1393US10669342B2Anti-OX40L antibodies and methods of treating graft versus host diseaseKYMAB LTD·Filed 2015·Granted Jun 2, 2020·7 cites·14 claims
- 1493US9434785B1Anti-human OX40L antibodies and methods of treating graft versus host disease with the sameKYMAB LTD·Filed 2015·Granted Sep 6, 2016·16 cites·30 claims
- 1591US11773175B2Antibodies, uses and methodsKYMAB LTD·Filed 2021·Granted Oct 3, 2023·1 cites·19 claims
- 1688US12209128B2Anti-PD-L1 antibodiesKYMAB LTD·Filed 2021·Granted Jan 28, 2025·1 cites·6 claims
- 1788US11965026B2Anti-PD-L1 and IL-2 cytokinesKYMAB LTD·Filed 2017·Granted Apr 23, 2024·3 cites·19 claims
- 1888US2024132605A1Antibodies, uses & methodsKYMAB LTD·Filed 2023·Application pending·0 cites
- 1987US2023270088A1Animal Models and Therapeutic MoleculesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2085US11858996B2Anti-ICOS antibodiesKYMAB LTD·Filed 2017·Granted Jan 2, 2024·2 cites·29 claims
- 2183US2024360218A1Anti-pd-l1 and il-2 cytokinesKYMAB LTD·Filed 2024·Application pending·0 cites
- 2283US2024343810A1Multispecific antibodies for immuno-oncologyKYMAB LTD·Filed 2024·Application pending·0 cites
- 2381US2024158502A1Anti-icos antibodiesKYMAB LTD·Filed 2023·Application pending·0 cites
- 2479US10259880B2Anti-LIGHT antibodiesKYMAB LTD·Filed 2015·Granted Apr 16, 2019·3 cites·30 claims
- 2579US2025263492A1Antibodies, uses & methodsKYMAB LTD·Filed 2025·Application pending·0 cites
- 2678US11753479B2Nucleic acids encoding anti-OX40L antibodiesKYMAB LTD·Filed 2020·Granted Sep 12, 2023·0 cites·21 claims
- 2778US9150653B2CD127 binding proteinsKIRBY IAN·Filed 2011·Granted Oct 6, 2015·5 cites·19 claims
- 2877US2022380467A1Anti-icos antibodiesKYMAB LTD·Filed 2022·Application pending·0 cites
- 2977US2022403029A1Anti-icos antibodiesKYMAB LTD·Filed 2022·Application pending·0 cites
- 3077US2023312720A1Multispecific antibodies for immuno-oncologyKYMAB LTD·Filed 2022·Application pending·0 cites
- 3176US8940303B2CD127 binding proteinsKIRBY IAN·Filed 2011·Granted Jan 27, 2015·6 cites·5 claims
- 3275US11440960B2TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivoKYMAB LTD·Filed 2018·Granted Sep 13, 2022·1 cites·14 claims
- 3372US11812731B2Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Granted Nov 14, 2023·0 cites·13 claims
- 3471US2014201854A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Application pending·0 cites
- 3571US2014201856A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2013·Application pending·0 cites
- 3670US9605063B2Antigen binding proteins to Oncostatin M (OSM)GLAXO GROUP LTD·Filed 2014·Granted Mar 28, 2017·1 cites·5 claims
- 3770US2023192847A1Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivoKYMAB LTD·Filed 2022·Application pending·0 cites
- 3870US2017071174A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 3970US2017099816A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4070US2017094956A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4169US2016345551A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2016·Application pending·0 cites
- 4269US2019276547A1Antibodies, uses & methodsKYMAB LTD·Filed 2018·Application pending·0 cites
- 4367US8916695B2Antigen binding proteins to oncostatin M (OSM)BEMBRIDGE GARY PETER·Filed 2011·Granted Dec 23, 2014·2 cites·16 claims
- 4467US2016044900A1Animal models and therapeutic moleculesKYMAB LTD·Filed 2015·Application pending·0 cites
- 4565US2021017270A1Antigen binding proteins to oncostatin m (osm)GLAXO GROUP LTD·Filed 2020·Application pending·0 cites
- 4663US2023201366A1Anti-psma conjugatesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 4763US2023285580A1Anti-il-13ralpha2 conjugatesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 4861US2022372153A1Synergistic combinations of ox40l antibodies for the treatment of gvhdKYMAB LTD·Filed 2022·Application pending·0 cites
- 4961US2012204278A1Animal models and therapeutic moleculesBRADLEY ALLAN·Filed 2011·Application pending·0 cites
- 5060US10808029B2Antigen binding proteins to oncostatin M (OSM)GLAXO GROUP LTD·Filed 2017·Granted Oct 20, 2020·0 cites·16 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ian Kirby files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →